The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
Microbial systems are a black box. We created Microbial INtelligence Explorer to “MINE” their secrets• Microbiotica Raises $48 Million Series C to Advance Pipeline into Phase 2 Clinical Development• Prokarium: Leading the Evolution of Bacterial Immunotherapy, the Next Frontier in Cancer Treatment• Claude Discovers Novel Enzyme System with CRISPR-like Repeats• New Clinical Study Aims to Find Out if FMT capsules could help better manage anorexia• MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination•

Category: Clinical & Manufacturing

Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 Study for the Prevention of Recurrent C. diff Infection
Clinical & Manufacturing

Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 Study for the Prevention of Recurrent C. diff Infection

MAY 22, 2024
SNIPR Biome receives funding from CARB-X for advancement of SNIPR001 into clinical trials in haematological cancer patients
Clinical & Manufacturing

SNIPR Biome receives funding from CARB-X for advancement of SNIPR001 into clinical trials in haematological cancer patients

APR 22, 2024
MRM Health Reports Safety and Positive Efficacy Data in Pouchitis in Phase 2a Clinical Study with MH002
Clinical & Manufacturing

MRM Health Reports Safety and Positive Efficacy Data in Pouchitis in Phase 2a Clinical Study with MH002

APR 16, 2024
EnteroBiotix Completes £27m Financing Round & Initiates Phase 2 Study in Patients with IBS
Clinical & Manufacturing

EnteroBiotix Completes £27m Financing Round & Initiates Phase 2 Study in Patients with IBS

APR 4, 2024
Initial patient dosed in Phase 2a clinical trial evaluating first-in-class human milk-based therapy
Clinical & Manufacturing

Initial patient dosed in Phase 2a clinical trial evaluating first-in-class human milk-based therapy

NOV 15, 2023
MaaT Pharma Announces First Patient Dosed in Phase 2b Randomized Clinical Trial Evaluating MaaT033 in Patients Receiving Allo-HSCT
Clinical & Manufacturing

MaaT Pharma Announces First Patient Dosed in Phase 2b Randomized Clinical Trial Evaluating MaaT033 in Patients Receiving Allo-HSCT

NOV 7, 2023
Kanvas Biosciences Acquires Federation Bio Assets to Scale Discovery, Development and Manufacturing
Clinical & Manufacturing

Kanvas Biosciences Acquires Federation Bio Assets to Scale Discovery, Development and Manufacturing

OCT 12, 2023
First Patient Dosed in Phase 2 Clinical Trial of Vedanta’s VE202 for the Treatment of Ulcerative Colitis
Clinical & Manufacturing

First Patient Dosed in Phase 2 Clinical Trial of Vedanta’s VE202 for the Treatment of Ulcerative Colitis

OCT 5, 2023
MRM Health Reports Positive Topline Results from Phase 2a Clinical Study with MH002 in Mild-to-Moderate Ulcerative Colitis
Clinical & Manufacturing

MRM Health Reports Positive Topline Results from Phase 2a Clinical Study with MH002 in Mild-to-Moderate Ulcerative Colitis

SEP 19, 2023
Bloom Science Announces Positive Topline Data from a Phase 1 Clinical Trial
Clinical & Manufacturing

Bloom Science Announces Positive Topline Data from a Phase 1 Clinical Trial

AUG 18, 2023
Freya Biosciences Announces Positive Topline Clinical Trial Results for FB101 in Women with Asymptomatic Vaginal Dysbiosis
Clinical & Manufacturing

Freya Biosciences Announces Positive Topline Clinical Trial Results for FB101 in Women with Asymptomatic Vaginal Dysbiosis

JUN 28, 2023